Loading company…
Sironax develops therapies for age-related degenerative diseases.
Sironax researches inhibitors targeting cell death, neuroprotective pathways, and neuroinflammation. Its pipeline includes the RIPK1 inhibitors SIR0365 and SIR2446. Established in 2017, the company is based in Beijing, China, and operates in China and the United States. It raised USD 200 million in Series B funding in August 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in